INSANE: Abbvie - The Real Truth

At-Home Skyrizi Induction Approved for Crohn's After 56% Reached Clinical Remission at 12 Weeks Versus 30% on Placebo

FDA approved at-home Skyrizi induction for Crohn's, with 56% reaching remission vs. 30% on placebo. What the results mean and key safety notes.

Medical Daily · 3h ago

3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach

Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.

MarketBeat · Oct 23

AbbVie’s Q3 2026 Earnings: What to Expect

Biopharma giant AbbVie is set to report its Q3 results on Oct. 30.

Barchart · Oct 15

3 Healthcare Dividend Stocks Offering More Than Just Income

AbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027.

MarketBeat · Sep 30

AbbVie's Once-Daily Parkinson's Pill Juvmo Wins FDA Approval, with Nausea, Dizziness, and Headache Common in Trials

The FDA approved Juvmo (tavapadon), AbbVie's once-daily Parkinson's pill. Here's how it works, which side effects trials found, and what to ask.

Medical Daily · Sep 28

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It

Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.

MarketBeat · Sep 6

An Experimental Myeloma Drug Given Monthly Outperformed Standard Options in Patients Who Exhausted Three Treatment Classes

AbbVie reports that its investigational drug etentamig produced a 74% response rate in relapsed multiple myeloma, against 45.7% for standard therapies.

Medical Daily · Sep 5

How Is AbbVie’s Stock Performance Compared to Other Healthcare Stocks

AbbVie has underperformed the healthcare peers over the past year, and analysts remain very optimistic about the stock’s outlook.

Barchart · Aug 30

Advocacy Group Says a Medicare Rule Change Delayed Price Negotiation for a Costly AbbVie Drug by Seven Years

Public Citizen says a CMS eligibility change kept AbbVie's Creon out of Medicare price negotiation for seven extra years. Here is how it works.

Medical Daily · Aug 10

What Are Wall Street Analysts' Target Price for AbbVie Stock?

Despite AbbVie’s outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.

Barchart · Aug 3